Related Experiment Video
Updated: Jan 5, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study
Ye Liu1, Jingxuan Zhu1, Xiaoqing Guo1
1Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun, China.
Abstract:
Approximately 30% of all types of human cancers possess a constitutively activated the mitogen-activated protein kinase (MAPK) signaling pathway while MAP kinase 1 (MEK1) is a critical component of this pathway. It has been reported mutations could improve the activity of MEK1 to result in cell proliferation and transformation, which is a known oncogenic event in various cancer types. In this study, eight molecular dynamics simulations, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA), combined with protein structure network were performed to explore the mechanism that mutations activate MEK1. Protein structure networks and hydrogen bonds analysis demonstrated that active mutations broke the interaction between activation segments (residues 216-222) and C-helix (residues 105-121) in MEK1, leading to it transform inactive form to active form. Moreover, hydrogen bond analysis and MM-PBSA calculation indicated that activating mutations decrease the binding affinity between MEK1 and inhibitor to reduce the inhibitory effect of inhibitors. In addition, some active mutations cause structural changes in the Pro-rich loop (residues 261-268) of MEK1. These changes may stabilize the interaction between the MEK1 mutants and the ligands by increasing the number of exposed hydrophobic residues in the active site of MEK1. Our results may provide useful theoretical evidences for the mechanism underlying the role of human MEK1 in human cancers.Communicated by Ramaswamy H. Sarma.
Insights
Activating mutations in MAP kinase 1 (MEK1) promote cancer by altering its structure and reducing inhibitor effectiveness. This study reveals how these mutations transform MEK1 into its active form, driving cell proliferation.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- The mitogen-activated protein kinase (MAPK) pathway is constitutively activated in ~30% of human cancers.
- MAP kinase 1 (MEK1) is a key component of the MAPK pathway, and its mutations can lead to oncogenic cell proliferation and transformation.
Purpose of the Study:
- To elucidate the molecular mechanisms by which mutations activate MEK1.
- To understand how MEK1 mutations affect its interaction with inhibitors.
Main Methods:
- Eight molecular dynamics simulations.
- Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) calculations.
- Protein structure network analysis.
- Hydrogen bond analysis.
Main Results:
- Activating mutations disrupt the interaction between MEK1's activation segments and C-helix, converting it to an active form.
- Mutations decrease MEK1's binding affinity for inhibitors, reducing their efficacy.
- Specific mutations alter the Pro-rich loop, potentially stabilizing MEK1-ligand interactions through increased hydrophobic residue exposure.
Conclusions:
- The study provides theoretical evidence for the mechanism of MEK1 activation by mutations in cancer.
- Findings offer insights into MEK1's role in oncogenesis and potential therapeutic strategies.
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

